Niagen Bioscience Inc (NAGE) is a publicly traded company in the Healthcare — Biotechnology industry listed on NASDAQ. This overview shows the latest price, key valuation ratios, profitability metrics and financial-health indicators used by fundamental investors.
Niagen Bioscience, Inc. operates as a bioscience company engages in developing healthy aging products. The company operates through Consumer products; Ingredients; and Pharmaceutical Segments. It provides finished dietary supplement products that contain its proprietary ingredients directly to consumers and distributors; nicotinamide adenine dinucleotide (NAD+), an essential coenzyme that regulates cellular metabolism; and develops and commercializes proprietary-based ingredi...
Analysis Summary
Niagen Bioscience Inc reported revenue of $129.4M in the most recent fiscal year, growing at a 5-year CAGR of 16.9%.
Trailing-twelve-month margins: gross margin 64.2%, operating margin 6.7%, net margin 12.4%.
At the current price of $3.00, NAGE trades at a P/E of 15.45 and an ROE of 20.50%. Market capitalisation stands at $239M.
Balance sheet quality for NAGE: current ratio of 4.9, net cash position of $62.0M. A debt-to-equity below 1.0 typically signals conservative capital structure, while a current ratio above 1.5 indicates comfortable short-term liquidity.
Cash flow quality is decent: free cash flow of $13.1M represents 76% conversion of reported net income. High conversion (above 90%) suggests earnings translate cleanly into cash; lower conversion may indicate working capital tightness or accounting timing differences.
Price
| Price | $3.00 |
| Market Cap | $239M |
| Exchange | NASDAQ |
| Country | US |
Valuation Ratios
| P/E Ratio | 15.45 |
| Price / Book | 2.88 |
| EV / EBITDA | 9.62 |
| Dividend Yield | 0.00% |
Profitability
| Return on Equity | 20.50% |
| Return on Invested Capital | 8.75% |
| Return on Assets | 15.00% |
| Gross Margin | 64.24% |
| Operating Margin | 6.67% |
| Net Margin | 12.39% |
Financial Health
| Debt / Equity | 0.03 |
| Current Ratio | 6.50 |
| Piotroski F-Score | 7 |
| Altman Z-Score | 10.48 |
What to look at in Biotech
Most small biotechs lose money. Analysing them with P/E makes no sense — look at cash and pipeline.
- Cash Runway — Months of cash at current burn rate. <18 months = urgent dilution risk
- Annual cash burn — Rate at which they burn operating cash. Compare with cash position to project runway
- Total Debt — Biotech with no revenue + debt = recipe for bankruptcy
- R&D / Market cap — How much they invest in pipeline vs the company value — research-intensity indicator
- Market cap / Cash — If it trades near its cash, the market assigns ~0 value to the pipeline — opportunity or trap
Peer Comparison
| Symbol | Company | Market Cap | P/E | P/B | ROE |
|---|---|---|---|---|---|
| NAGE | Niagen Bioscience Inc | $239M | 15.45 | 2.88 | 20.5% |
| 0QZU.L | Vertex Pharmaceuticals Incorporated | $131.8B | |||
| VRTX | Vertex Pharmaceuticals Incorporated | $130.6B | 29.76 | 6.46 | 23.3% |
| 0R2M.L | Regeneron Pharmaceuticals, Inc. | $84.0B | |||
| REGN | Regeneron Pharmaceuticals, Inc. | $79.8B | 18.79 | 2.57 | 13.8% |
| ARGX | argenx SE | $61.2B | 36.30 | 7.40 | 21.7% |
| MRNA | Moderna, Inc. | $57.8B | 1.34 | -39.2% | |
| RVMD | Revolution Medicines, Inc. | $41.7B | 15.96 | -96.4% |
Price Performance
| 1 month | -1.96% |
| 3 months | -14.29% |
| Year-to-date | -52.83% |
| 1 year | -68.85% |
| 3 years | +114.29% |
| 5 years | -55.69% |
52-Week Range
| 52-week High | $10.52 |
| 52-week Low | $2.87 |
| Avg Volume (90d) | 723K |
Related companies: AKBA · CRVS · KALV · KROS · OLMA · PRTA · RGNX
Explore sector: Healthcare · Biotechnology
More sections of NAGE: Financials · Valuation · Statistics · Estimates · Technical · Ownership · News · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks